UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Find beginner-friendly options with understandable use cases and liquidity, plus a simple framework to compare potential investments.
27,615 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
As Oracle prepares to report its Q4 2026 results, investors are weighing the cloud growth story, AI bets, and margin ...
Asana has fallen from pandemic highs, but buying the dip isn’t a guaranteed win. This guide explains the risks, what ...
Get a clear, investor-friendly view of Perion's 2025 earnings outlook. This guide explains revenue drivers, margins, ...
Investors have watched Peloton stumble from its pandemic-era peak to today’s volatile trading. This guide digs into w...
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
A surprising analyst upgrade helped StubHub Holdings stock crush expectations this week. This article breaks down the...
Think AI stocks can’t deliver both growth and income? This piece reveals two surprising dividend plays that tap AI tr...
AppLovin shares slipped in June as software peers faced headwinds. This in-depth look explains the catalysts, how the...
Casual dining is turning a corner. Chili's posted an eye-catching 8.6% same-store sales gain, signaling a broader shi...
WM Technology MAPS is weighing a pivotal year. This guide breaks down the Q4 2025 earnings, what technology (maps) 20...
As Progyny gears up for 2026, investors want clarity on what drives progyny (pgny) 2026 earnings. This guide breaks d...